



(51) International Patent Classification:

A61K 31/497 (2006.01) A61K 31/4439 (2006.01)

A61K 9/00 (2006.01) A61K 45/06 (2006.01)

A61K 9/20 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/EP2023/080652

(22) International Filing Date:

03 November 2023 (03.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/382,311 04 November 2022 (04.11.2022) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: OWEN, Caroline Ann; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). PROTHON, Susanne; AstraZeneca AB, SE-151 85 Södertälje (SE). WILLIAMS, Michael Lee; AstraZeneca AB, SE-151 85 Södertälje (SE). FERRARI, Nicola; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). WIKSTRÖM, Håkan; AstraZeneca AB, SE-151 85 Södertälje (SE). SJÖSTRAND, Veronika; AstraZeneca AB, SE-151 85 Södertälje (SE). FRANSSON, Rebecca; AstraZeneca AB, SE-151 85 Södertälje (SE). CHUKHARKINA, Alexandra Pavlovna; AstraZeneca AB, SE-151 85 Södertälje (SE).

(74) Agent: ASTRAZENECA INTELLECTUAL PROPERTY; Association No. 813, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ORAL FORMULATION OF N-PYRIDINYL ACETAMIDE DERIVATIVE FOR TREATING INTERSTITIAL LUNG DISEASE

(57) Abstract: The present disclosure relates to oral formulations of an n-pyridinyl acetamide derivative, and the use of such formulations in the treatment of interstitial lung diseases.

